Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04741646 · ClinicalTrials.gov registry record · Phase 2
Ferric Citrate and Chronic Kidney Disease in Children
A Phase 2 study of Chronic Kidney Diseases, sponsored by University of California, Los Angeles.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 160
- Enrollment target
- 20
- Study locations
NCT04741646: Recruiting Phase 2 study of Chronic Kidney Diseases, sponsored by University of California, Los Angeles.
NCT04741646 is a Phase 2 study of Chronic Kidney Diseases that is actively recruiting participants, run by University of California, Los Angeles. The registered enrollment target is 160 participants, below the 443-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04741646, a Phase 2 study of Chronic Kidney Diseases, is actively recruiting participants, sponsored by University of California, Los Angeles.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 160 participants
- Enrollment target
- 20
- Study locations
Study Summary
We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidney disease (CKD) stages 3-4 and age-appropriate normal serum phosphate levels. Participants will be randomized to one of the two groups: 1) FC or 2) FC placebo. Participants will be recruited from 20 core clinical sites.
Primary Outcome
Compared to placebo, active treatment with FC will lower iFGF23 levels
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Ferric Citrate
Study Locations (20)
California
- University of California, Los Angeles - Los Angeles
- Children's Hospital of Orange County - Orange
- University of California, San Francisco - San Francisco
Texas
- Children's Medical Center, Dallas - Dallas
- Baylor College of Medicine - Houston
- UTH - Houston
Missouri
- Children's Mercy Hospital, Kansas City - Kansas City
- Washington U - St Louis
New York
- Cohen's Childrens - New York
- Children's Hospital at Montefiore - The Bronx
Ohio
- Cincinnati Children's Hospital Medical Center - Cincinnati
- Nationwide Children's - Columbus
Florida
- Arnold Palmer Hospital for Children - Orlando
Georgia
- Emory University - Atlanta
Indiana
- Indiana U - Indianapolis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2022-06-17 |
| Est. Completion | 2027-10 |
| Phase | Phase 2 |
What NCT04741646 shows while recruiting
NCT04741646 is an interventional study that assigns participants to a tested intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap, below the 443-participant average among 73 other Chronic Kidney Diseases trials with a reported enrollment target (64% lower).
The record links to 1 condition, with Chronic Kidney Diseases appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04741646 names 20 study sites across 13 states, led by California, Texas, Missouri.
Frequently Asked Questions
What is clinical trial NCT04741646 about?
NCT04741646 is a clinical study titled "Ferric Citrate and Chronic Kidney Disease in Children". We will conduct a 12-month, double-blind, randomized, placebo-controlled trial to assess the effects of therapy with ferric citrate (FC) on changes in intact FGF23 levels (iFGF23, primary endpoint) in 160 pediatric patients (80 in each of the two arms) aged 6-18 years of either sex with chronic kidn...
What is the current status of trial NCT04741646?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 160 participants. The study started on 2022-06-17. Estimated completion is 2027-10.
What conditions does trial NCT04741646 study?
This clinical trial studies the following conditions: Chronic Kidney Diseases.
What interventions are being tested in trial NCT04741646?
The interventions under investigation include: Placebo (DRUG), Ferric Citrate (DRUG).
Who is sponsoring clinical trial NCT04741646?
This trial is sponsored by University of California, Los Angeles, which has 897 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04741646 being conducted?
This trial has 20 study locations across California, Florida, Georgia, Indiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chronic Kidney Diseases
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04741646's enrollment target sits among peer trials
160 30th of 73 higher than 44 of 73 other Chronic Kidney Diseases trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Chronic Kidney Diseases trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sodium Bicarbonate and Mitochondrial Energetics in Persons With CKD
RECRUITING · Phase 2
-
Anti-Inflammatory Treatment of Uremic Cardiomyopathy With Colchicine
RECRUITING · Phase 2
-
Bone in CKD Alkali Response (BICARb Pilot Trial)
RECRUITING · Phase 2
-
Combination of Novel Therapies for CKD Comorbid Depression
RECRUITING · Phase 2
-
Acute Equol Supplementation and Vascular Function in Women With and Without CKD
RECRUITING · Phase 2
-
Sit Less, Interact and Move More (SLIMM) 2 Study
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI